Söktas Tekstil Sanayi Ve Ticaret A.S. (IST:SKTAS)

Marinus Pharmaceuticals Balance Sheet

Financials in millions TRY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	28.69	42.46	127.04	73.41	45.19	41.23
Cash & Short-Term Investments	28.69	42.46	127.04	73.41	45.19	41.23
Cash Growth	-56.64%	-66.58%	73.05%	62.45%	9.60%	142.99%
Accounts Receivable	157.46	188.52	325.13	324.91	77.02	46.57
Other Receivables	18.08	8.7	32.13	34.15	17.53	13.49
Receivables	175.54	197.22	357.25	359.06	94.56	60.06
Inventory	512.24	527.03	641.5	518.02	165.32	79.47
Prepaid Expenses	11.4	12.57	15	10.18	4.24	4.7
Other Current Assets	3.6	2.54	27.23	19.26	1.45	4.57
Total Current Assets	731.46	781.81	1,168	979.94	310.75	190.03
Property, Plant & Equipment	2,579	2,355	3,434	2,194	790.7	439.67
Long-Term Investments	13.91	13.98	20.35	13.64	2.3	1.21
Other Intangible Assets	6.77	6.48	9.68	7.52	2.32	2.51
Long-Term Deferred Charges	-	-	0.67	1.47	2.18	3.01
Other Long-Term Assets	2.01	1.9	220.28	399.08	237.64	166.7
Total Assets	3,333	3,159	4,853	3,595	1,346	803.13
Accounts Payable	237.02	292.8	549.28	493.2	183.97	95.29
Accrued Expenses	121.24	100.92	107.66	52.74	17.16	10.68
Short-Term Debt	435.14	396.9	685.28	554.47	192.12	138.17
Current Portion of Long-Term Debt	81.5	56.15	121.39	283.15	126.99	88.3
Current Portion of Leases	23.92	22.42	28.09	1.96	13.63	10.79
Current Income Taxes Payable	-	-	-	0.27	0.02	-
Current Unearned Revenue	12.42	22.05	71.74	44.83	12.54	3.72
Other Current Liabilities	55.11	35.61	4.39	44.98	0.93	0.61
Total Current Liabilities	966.36	926.86	1,568	1,476	547.35	347.56
Long-Term Debt	27.99	53.08	335.06	192.02	175.9	173.47
Long-Term Leases	13.08	16.99	57.91	0.8	13.42	10.97
Long-Term Unearned Revenue	-	-	-	-	-	0.19
Long-Term Deferred Tax Liabilities	413.03	369	380.75	231.9	71.53	51.78
Other Long-Term Liabilities	17.15	123.65	145.26	1.14	5.3	7.45
Total Liabilities	1,526	1,490	2,487	2,101	854.97	619.78
Common Stock	222	222	222	153.8	153.8	78.23
Additional Paid-In Capital	10.85	9.85	92.6	62.5	15.02	14.53
Retained Earnings	-1,709	-1,541	-1,737	-1,257	-231.68	-247.83
Comprehensive Income & Other	3,282	2,978	3,546	2,375	498.36	304.7
Total Common Equity	1,805	1,669	2,123	1,334	435.49	149.64
Minority Interest	1.13	0.6	243.23	160.57	55.44	33.71
Shareholders' Equity	1,807	1,670	2,367	1,494	490.93	183.35
Total Liabilities & Equity	3,333	3,159	4,853	3,595	1,346	803.13
Total Debt	581.64	545.54	1,228	1,032	522.05	421.71
Net Cash (Debt)	-552.95	-503.08	-1,101	-958.99	-476.86	-380.47
Net Cash Per Share	-2.49	-2.27	-5.97	-6.24	-4.63	-6.85
Filing Date Shares Outstanding	222	222	222	153.8	153.8	78.23
Total Common Shares Outstanding	222	222	222	153.8	153.8	78.23
Working Capital	-234.89	-145.05	-399.81	-495.66	-236.6	-157.53
Book Value Per Share	8.13	7.52	9.56	8.67	2.83	1.91
Tangible Book Value	1,799	1,663	2,114	1,326	433.17	147.13
Tangible Book Value Per Share	8.10	7.49	9.52	8.62	2.82	1.88
Land	1,398	1,270	1,934	1,193	465.7	237.32
Buildings	995.44	904.2	1,455	964.91	204.82	166.08
Machinery	3,152	2,858	3,132	2,103	296.31	193.43
Construction In Progress	4.16	3.78	16.55	15.42	3.66	4.21
Leasehold Improvements	3.72	3.38	3.71	2.03	0.87	0.78

Source: S&P Global Market Intelligence. Standard template. Financial Sources.